Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208.
Moinpour CM, Unger JM, Ganz PA, Kornblith AB, Gaynor ER, Bowers MA, Gatti GS, Kaminski MS, Erba HP, Wang T, Yoon J, Press OW, Fisher RI. Moinpour CM, et al. Among authors: gaynor er. J Cancer Surviv. 2017 Feb;11(1):32-40. doi: 10.1007/s11764-016-0559-y. Epub 2016 Jul 12. J Cancer Surviv. 2017. PMID: 27405732 Free PMC article. Clinical Trial.
Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma.
Gaynor ER, Weiss GR, Margolin KA, Aronson FR, Sznol M, Demchak P, Grima KM, Fisher RI, Boldt DH, Doroshow JH, et al. Gaynor ER, et al. J Natl Cancer Inst. 1990 Sep 5;82(17):1397-402. doi: 10.1093/jnci/82.17.1397. J Natl Cancer Inst. 1990. PMID: 2388289
Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809.
Fisher RI, Dana BW, LeBlanc M, Kjeldsberg C, Forman JD, Unger JM, Balcerzak SP, Gaynor ER, Roy V, Miller T. Fisher RI, et al. Among authors: gaynor er. J Clin Oncol. 2000 May;18(10):2010-6. doi: 10.1200/JCO.2000.18.10.2010. J Clin Oncol. 2000. PMID: 10811664 Clinical Trial.
A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study.
Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP. Fisher RI, et al. Among authors: gaynor er. Ann Oncol. 1994;5 Suppl 2:91-5. doi: 10.1093/annonc/5.suppl_2.s91. Ann Oncol. 1994. PMID: 7515652 Clinical Trial.
41 results